Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TTPH

Tetraphase Pharmaceuticals (TTPH) Stock Price, News & Analysis

Tetraphase Pharmaceuticals logo

About Tetraphase Pharmaceuticals Stock (NASDAQ:TTPH)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$2.18
$2.27
50-Day Range
$2.20
$2.20
52-Week Range
$0.56
$8.60
Volume
282,689 shs
Average Volume
932,542 shs
Market Capitalization
$15.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

Remove Ads
Receive TTPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tetraphase Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TTPH Stock News Headlines

This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
TTPH_old Historical Data
10 Worst NASDAQ Biotech Stocks in the Third Quarter
See More Headlines

TTPH Stock Analysis - Frequently Asked Questions

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) posted its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.63) by $0.32. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to analysts' expectations of $2.45 million. Tetraphase Pharmaceuticals had a negative trailing twelve-month return on equity of 210.86% and a negative net margin of 798.18%.

Tetraphase Pharmaceuticals's stock reverse split on Friday, September 27th 2019. The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 26th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tetraphase Pharmaceuticals investors own include Alcoa (AA), Aurinia Pharmaceuticals (AUPH), General Electric (GE), Bank of America (BAC), OPKO Health (OPK), Novavax (NVAX) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
5/07/2020
Today
4/04/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TTPH
Fax
N/A
Employees
119
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-70,080,000.00
Net Margins
-798.18%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.38 million
Price / Cash Flow
N/A
Book Value
$6.68 per share
Price / Book
0.33

Miscellaneous

Free Float
N/A
Market Cap
$15.98 million
Optionable
Optionable
Beta
2.33
10 Stocks Set to Soar in Spring 2025 Cover

Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.

Get This Free Report

This page (NASDAQ:TTPH) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners